Filing Details

Accession Number:
0001209191-21-030625
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-05-06 13:00:00
Reporting Period:
2021-05-04
Accepted Time:
2021-05-06 16:19:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1785530 Werewolf Therapeutics Inc. HOWL () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1134655 Ansbert Gadicke C/o Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
1687078 Mpm Oncology Impact Management Lp C/o Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
1691428 L.p. Fund Impact Oncology Ubs C/o Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
1719960 Mpm Oncology Innovations Fund Lp C/o Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
1721035 Mpm Oncology Impact Management Gp Llc C/o Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
1721036 L.p. Management (Cayman) Fund Impact Oncology C/o Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
1857903 Mpm Oncology Innovations Fund Gp Llc C/o Mpm Capital
450 Kendall Street
Cambridge MA 02142
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-05-04 4,477,742 $0.00 4,939,150 No 4 C Indirect See Footnote
Common Stock Acquisiton 2021-05-04 1,488,033 $0.00 6,427,183 No 4 C Indirect See Footnote
Common Stock Acquisiton 2021-05-04 245,000 $16.00 6,672,183 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2021-05-04 38,817,998 $0.00 4,477,742 $0.00
Common Stock Series B Preferred Stock Disposition 2021-05-04 12,899,925 $0.00 1,488,033 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
  2. The shares are held as follows: 461,408 by MPM Asset Management LLC ("AM LLC"), 2,087,358 by MPM BioVentures 2014, L.P. ("BV 2014"), 139,224 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 71,848 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 457,643 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 1,721,669 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a member of AM LLC and a Managing Director of BV LLC. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF.
  3. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the managing director of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
  4. The shares are held as follows: 461,408 by AM LLC, 2,781,025 by BV 2014, 185,490 by BV 2014(B), 95,724 by AM BV2014, 609,726 by MPM OIF and 2,293,810 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
  5. The shares were purchased as follows: 114,210 by BV 2014, 7,618 by BV 2014(B), 3,931 by AM BV2014, 25,040 by MPM OIF and 94,201 by UBS Oncology.
  6. The shares are held as follows: 461,408 by AM LLC, 2,895,235 by BV 2014, 193,108 by BV 2014(B), 99,655 by AM BV2014, 634,766 by MPM OIF and 2,388,011 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
  7. The shares were held as follows: 2,087,358 by BV 2014, 139,224 by BV 2014(B), 71,848 by AM BV2014, 457,643 by MPM OIF and 1,721,669 by UBS Oncology.
  8. No securities held by the Reporting Persons.
  9. The shares were held as follows: 693,667 by BV 2014, 46,266 by BV 2014(B), 23,876 by AM BV2014, 152,083 by MPM OIF and 572,141 by UBS Oncology.